Phage Startup Wins Prize as Antibiotic Alternative
SciPhage's poultry product is patented in three countries, and its trout product is in field validation.
Updated on Nov. 5, 2026 in Life Sciences

Colombian startup SciPhage won the 2026 Innovate for Impact Challenge, earning a $65,000 first prize at the Norman E. Borlaug International Dialogue in Des Moines. SciPhage develops bacteriophages, viruses that target bacteria, as a natural alternative to antibiotics in livestock and aquaculture. The company's lead product is in use controlling Salmonella in poultry, and a second product for trout is in field validation.
Why it matters
The award highlights a growing push to replace antibiotics in animal agriculture with targeted biological alternatives. Because the challenge supports early-stage, for-profit agtech companies, it signals where investor and institutional attention in agricultural biotechnology is moving.
The competition narrowed more than 1,500 applications from over 100 countries to four finalists who pitched live before a judging panel. SciPhage's lead Salmonella-control product is patented in Colombia, the United States and Brazil, while performance data for the trout product remains under field validation.
The players
SciPhage (Ciencia y Tecnología de Fagos SciPhage S.A.S)
A Colombian agtech startup developing bacteriophage-based alternatives to antibiotics for poultry, aquaculture and livestock, spun out of the Universidad de los Andes.
Innovate for Impact Challenge
A competition in its second year that supports early-stage, for-profit agricultural technology startups.
Norman E. Borlaug International Dialogue
An annual international agricultural forum held in Des Moines, where the Innovate for Impact prize was presented.
The details
SciPhage builds on bacteriophages, viruses that infect and kill specific bacteria while leaving the host animal's cells alone. Because each phage typically targets a narrow group of bacteria, it can act against a pathogen such as Salmonella without the broad disruption antibiotics cause to gut microbes. The company was founded at the Universidad de los Andes in Colombia, and its lead product is patented across three countries.
Timeline
Borlaug International Dialogue held in Des Moines, where SciPhage received its prize (recent, date not specified in source).
The Tech Race
SciPhage's work sits within a field of agtech startups competing to supply alternatives to antibiotics as livestock and aquaculture producers look for options. The Innovate for Impact Challenge's selection from more than 1,500 applicants shows how crowded and competitive this early-stage space has become.
Farmers and aquaculture producers may eventually have phage-based options for controlling bacterial disease, though the source gives no commercial availability date or pricing. The trout product remains in field validation, so producers should not expect it in use until that work is complete.
The takeaway
The main takeaway is that bacteriophage products are moving from research toward commercial use in animal production. Readers should watch for published field efficacy results from SciPhage's trout validation and for the company's commercial launch timeline.
Further reading
For broader context on how these biological alternatives work, explore Life Sciences.
Source note: This article includes information reported by Business Record.


